Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Identifieur interne : 000604 ( Istex/Curation ); précédent : 000603; suivant : 000605Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit
Auteurs : Karen L. Eskow Jaunarajs [États-Unis] ; David G. Standaert [États-Unis] ; Tacey X. Viegas [États-Unis] ; Michael D. Bentley [États-Unis] ; Zhihao Fang [États-Unis] ; Bekir Dizman [États-Unis] ; Kunsang Yoon [États-Unis] ; Rebecca Weimer [États-Unis] ; Paula Ravenscroft [Canada] ; Tom H. Johnston [Canada] ; Michael P. Hill [Canada] ; Jonathan M. Brotchie [Canada] ; Randall W. Moreadith [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2013-10.
Abstract
Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease (PD) motor symptoms but often lead to significant motor complications including “wearing‐off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using polyoxazoline (POZ) polymer conjugation may improve motor symptoms, while avoiding development of side effects. The purposes of the current study are to characterize the in vitro and in vivo pharmacokinetics of POZ conjugation of a U.S. Food and Drug Administration (FDA)‐approved DA agonist, rotigotine, and to evaluate their effects in an established rat model of PD. After determination of release profiles of several POZ‐conjugated constructs (“fast”: SER‐212; “moderate”: SER‐213; and “slow”: SER‐214) using in vitro hydrolysis, normal male Sprague‐Dawley rats were used for determination of the pharmacokinetic profile of both acute and chronic exposure. Finally, a separate group of rats was rendered hemiparkinsonian using intracranial 6‐hydroxydopamine (6‐OHDA) infusions, treated acutely with POZ‐rotigotine, and assessed for rotational behavior and antiparkinsonian benefit using the cylinder test. POZ‐rotigotine formulations SER‐213 and SER‐214 led to substantial pharmacokinetic improvement compared to unconjugated rotigotine. In addition, SER‐214 led to antiparkinsonian effects in DA‐lesioned rats that persisted up to 5 days posttreatment. Repeated weekly dose administration of SER‐214 to normal rats for up to 12 weeks demonstrated highly reproducible pharmacokinetic profiles. The continuous dopaminergic stimulation profile afforded by SER‐214 could represent a significant advance in the treatment of PD, with potential to be a viable, once‐per‐week therapy for PD patients.
Url:
DOI: 10.1002/mds.25625
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000604
Links to Exploration step
ISTEX:4F7894514D755826E1536555A418DCCAF9D2765ELe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit</title>
<author><name sortKey="Eskow Jaunarajs, Karen L" sort="Eskow Jaunarajs, Karen L" uniqKey="Eskow Jaunarajs K" first="Karen L." last="Eskow Jaunarajs">Karen L. Eskow Jaunarajs</name>
<affiliation wicri:level="1"><mods:affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name>
<affiliation wicri:level="1"><mods:affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: dstandaert@uab.edu</mods:affiliation>
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Viegas, Tacey X" sort="Viegas, Tacey X" uniqKey="Viegas T" first="Tacey X." last="Viegas">Tacey X. Viegas</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bentley, Michael D" sort="Bentley, Michael D" uniqKey="Bentley M" first="Michael D." last="Bentley">Michael D. Bentley</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fang, Zhihao" sort="Fang, Zhihao" uniqKey="Fang Z" first="Zhihao" last="Fang">Zhihao Fang</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dizman, Bekir" sort="Dizman, Bekir" uniqKey="Dizman B" first="Bekir" last="Dizman">Bekir Dizman</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yoon, Kunsang" sort="Yoon, Kunsang" uniqKey="Yoon K" first="Kunsang" last="Yoon">Kunsang Yoon</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weimer, Rebecca" sort="Weimer, Rebecca" uniqKey="Weimer R" first="Rebecca" last="Weimer">Rebecca Weimer</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moreadith, Randall W" sort="Moreadith, Randall W" uniqKey="Moreadith R" first="Randall W." last="Moreadith">Randall W. Moreadith</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4F7894514D755826E1536555A418DCCAF9D2765E</idno>
<date when="2013" year="2013">2013</date>
<idno type="doi">10.1002/mds.25625</idno>
<idno type="url">https://api-v5.istex.fr/document/4F7894514D755826E1536555A418DCCAF9D2765E/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000604</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000604</idno>
<idno type="wicri:Area/Istex/Curation">000604</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit</title>
<author><name sortKey="Eskow Jaunarajs, Karen L" sort="Eskow Jaunarajs, Karen L" uniqKey="Eskow Jaunarajs K" first="Karen L." last="Eskow Jaunarajs">Karen L. Eskow Jaunarajs</name>
<affiliation wicri:level="1"><mods:affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Standaert, David G" sort="Standaert, David G" uniqKey="Standaert D" first="David G." last="Standaert">David G. Standaert</name>
<affiliation wicri:level="1"><mods:affiliation>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama‐Birmingham, Alabama, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>E-mail: dstandaert@uab.edu</mods:affiliation>
<country wicri:rule="url">États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Viegas, Tacey X" sort="Viegas, Tacey X" uniqKey="Viegas T" first="Tacey X." last="Viegas">Tacey X. Viegas</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bentley, Michael D" sort="Bentley, Michael D" uniqKey="Bentley M" first="Michael D." last="Bentley">Michael D. Bentley</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Fang, Zhihao" sort="Fang, Zhihao" uniqKey="Fang Z" first="Zhihao" last="Fang">Zhihao Fang</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Dizman, Bekir" sort="Dizman, Bekir" uniqKey="Dizman B" first="Bekir" last="Dizman">Bekir Dizman</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yoon, Kunsang" sort="Yoon, Kunsang" uniqKey="Yoon K" first="Kunsang" last="Yoon">Kunsang Yoon</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Weimer, Rebecca" sort="Weimer, Rebecca" uniqKey="Weimer R" first="Rebecca" last="Weimer">Rebecca Weimer</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ravenscroft, Paula" sort="Ravenscroft, Paula" uniqKey="Ravenscroft P" first="Paula" last="Ravenscroft">Paula Ravenscroft</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Johnston, Tom H" sort="Johnston, Tom H" uniqKey="Johnston T" first="Tom H." last="Johnston">Tom H. Johnston</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hill, Michael P" sort="Hill, Michael P" uniqKey="Hill M" first="Michael P." last="Hill">Michael P. Hill</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Brotchie, Jonathan M" sort="Brotchie, Jonathan M" uniqKey="Brotchie J" first="Jonathan M." last="Brotchie">Jonathan M. Brotchie</name>
<affiliation wicri:level="1"><mods:affiliation>Atuka Ltd., Ontario, Toronto, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Atuka Ltd., Ontario, Toronto</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Moreadith, Randall W" sort="Moreadith, Randall W" uniqKey="Moreadith R" first="Randall W." last="Moreadith">Randall W. Moreadith</name>
<affiliation wicri:level="1"><mods:affiliation>Serina Therapeutics, Inc., Alabama, Huntsville, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Serina Therapeutics, Inc., Alabama, Huntsville</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Blackwell Publishing Ltd</publisher>
<date type="published" when="2013-10">2013-10</date>
<biblScope unit="volume">28</biblScope>
<biblScope unit="issue">12</biblScope>
<biblScope unit="page" from="1675">1675</biblScope>
<biblScope unit="page" to="1682">1682</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">4F7894514D755826E1536555A418DCCAF9D2765E</idno>
<idno type="DOI">10.1002/mds.25625</idno>
<idno type="ArticleID">MDS25625</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract">Currently available dopaminergic drugs such as levodopa and dopamine (DA) receptor agonists impart considerable improvement in Parkinson's disease (PD) motor symptoms but often lead to significant motor complications including “wearing‐off” and dyskinesia. Such complications are believed to stem from the pulsatile nature of dopaminergic stimulation with these agents. Continuous dopaminergic drug delivery using polyoxazoline (POZ) polymer conjugation may improve motor symptoms, while avoiding development of side effects. The purposes of the current study are to characterize the in vitro and in vivo pharmacokinetics of POZ conjugation of a U.S. Food and Drug Administration (FDA)‐approved DA agonist, rotigotine, and to evaluate their effects in an established rat model of PD. After determination of release profiles of several POZ‐conjugated constructs (“fast”: SER‐212; “moderate”: SER‐213; and “slow”: SER‐214) using in vitro hydrolysis, normal male Sprague‐Dawley rats were used for determination of the pharmacokinetic profile of both acute and chronic exposure. Finally, a separate group of rats was rendered hemiparkinsonian using intracranial 6‐hydroxydopamine (6‐OHDA) infusions, treated acutely with POZ‐rotigotine, and assessed for rotational behavior and antiparkinsonian benefit using the cylinder test. POZ‐rotigotine formulations SER‐213 and SER‐214 led to substantial pharmacokinetic improvement compared to unconjugated rotigotine. In addition, SER‐214 led to antiparkinsonian effects in DA‐lesioned rats that persisted up to 5 days posttreatment. Repeated weekly dose administration of SER‐214 to normal rats for up to 12 weeks demonstrated highly reproducible pharmacokinetic profiles. The continuous dopaminergic stimulation profile afforded by SER‐214 could represent a significant advance in the treatment of PD, with potential to be a viable, once‐per‐week therapy for PD patients.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000604 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000604 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:4F7894514D755826E1536555A418DCCAF9D2765E |texte= Rotigotine polyoxazoline conjugate SER‐214 provides robust and sustained antiparkinsonian benefit }}
This area was generated with Dilib version V0.6.29. |